Comprehensive Study Notes on Iron Overload and Clinical Management of Iron Overload

Overview of Iron Overload

  • Definition: Iron overload, also known as Hemochromatosis, is a medical condition characterized by the accumulation of excessive iron within body tissues. This accumulation primarily affects the liver, heart, and pancreas, potentially leading to organ failure.
  • Categorization:
    • Primary (Hereditary): This form stems from genetic factors that cause the body to absorb too much iron.
    • Secondary: This form arises from external factors or underlying conditions such as repeated blood transfusions or chronic liver disease.
  • General Pathophysiology:
    • Excessive accumulation eventually leads to tissue damage.
    • Parenchymal iron overload often occurs due to excessive intestinal absorption.
    • Parenterally administered iron (e.g., via transfusions) is initially taken up by macrophages in senescent red cells.
    • There is no absolute distinction between these sources, as macrophage iron is slowly released to transferrin and subsequently taken up by parenchymal cells.
  • Severity Threshold: Severe iron overload is arbitrarily defined as an excess of more than 5 g5\,g. This level is typically confined to genetic hemochromatosis, iron-loading anemias, and sub-Saharan African dietary iron overload.

Case Scenario: 18-Year-Old Thalassemic Patient

  • Clinical Presentation:
    • Age: 18 years old.
    • Condition: Known thalassaemic.
    • Symptoms: Abdominal pain, joint pain, shortness of breath, dizziness, and headache.
    • Past Medical History (PMH): Regular blood transfusions twice per month.
    • Physical Examination (O/E): Pale, jaundiced, distended abdomen. Mild tenderness on the Right metacarpophalangeal (MCP) joints.
  • Analysis Questions:
    • Question 1: Explain the patient’s clinical condition.
    • Question 2: What are the reasons for his condition?
    • Question 3: What tests will you request for him and explain why for each?
    • Question 4: What are the expected complications specific for his condition?

Causes and Classification of Iron Overload

Severe Iron Overload (>5 g>5\,g excess)

  • Excess Iron Absorption:
    • Hereditary haemochromatosis.
    • Massive ineffective erythropoiesis (e.g., β\beta-thalassaemia intermedia, sideroblastic anaemia, congenital dyserythropoietic anaemia).
  • Increased Iron Intake:
    • Sub-Saharan dietary iron overload (often combined with a genetic determinant of increased absorption).
  • Excess Parenteral Iron Therapy:
    • Repeated red cell transfusions for congenital anaemias (e.g., β\beta-thalassaemia major, sickle cell anaemia, red cell aplasia).
    • Acquired refractory anaemias (e.g., myelodysplasia, aplastic anaemia).

Modest Iron Overload (<5 g<5\,g excess)

  • Chronic liver disease (e.g., alcoholic cirrhosis).
  • Porphyria cutanea tarda.
  • Rare genetic disorders (e.g., atransferrinaemia, acaeruloplasminaemia, DMT1 mutations).

Focal Iron Overload

  • Pulmonary haemorrhage or idiopathic pulmonary haemosiderosis.
  • Chronic haemoglobinuria (e.g., paroxysmal nocturnal haemoglobinuria).

Genetic Haemochromatosis Types

  • Type 1 (HFE-associated):
    • Gene: HFE (atypical MHC class I-like gene on chromosome 6).
    • Inheritance: Autosomal Recessive (AR).
    • Severity: Highly variable.
    • Incidence: Common, particularly in Northern European populations.
    • Mutations: 90% are homozygous for the Cys282TyrCys282Tyr (C282Y) mutation (G→AG \rightarrow A substitution at nucleotide 845). A second variant is His63AspHis63Asp (H63D).
  • Type 2 (Juvenile Haemochromatosis):
    • Gene: Hemojuvelin (HFE2) or Hepcidin (HAMP).
    • Inheritance: Autosomal Recessive (AR).
    • Severity: Severe; onset often in teenagers or individuals in their early 20s (as low as age 5).
    • Incidence: Rare.
  • Type 3:
    • Gene: Transferrin receptor 2 (TFR2).
    • Inheritance: Autosomal Recessive (AR).
    • Severity: Variable.
    • Incidence: Rare.
  • Type 4 (Ferroportin Disease):
    • Gene: Ferroportin 1 (SLC11A3).
    • Inheritance: Autosomal Dominant (AD).
    • Severity: Variable.
    • Incidence: Rare.

Pathophysiology of Type 1 Haemochromatosis

  • Nature of Defect: Deficient hepcidin production leads to unregulated intestinal iron absorption and increased mucosal iron transfer to plasma.
  • Hepcidin Function: Hepcidin is a negative regulator of iron. It binds to ferroportin, causing its internalization and lysosomal degradation.
  • Impact of Low Hepcidin:
    • Upregulates ferroportin in the duodenal mucosa.
    • Increases mucosal iron transfer to transferrin.
    • Leaves duodenal cells iron deficient.
    • Macrophages fail to retain iron, leading to low iron levels in macrophages and high serum iron in early stages.
  • Modifiers of Phenotype:
    • Full expression depends on dietary iron intake, blood loss (including menstruation and pregnancy), and modifying genetic factors.

Clinical Presentation and Complications

  • Liver: Cirrhosis. Hepatocellular carcinoma develops in 25% of cases with established cirrhosis. Hepatic enlargement may cause abdominal pain.
  • Endocrine:
    • Diabetes mellitus (from iron deposition in pancreatic islets).
    • Hypogonadism (gonadal failure).
    • Hypothyroidism and hypoparathyroidism (common in poorly chelated patients).
    • Growth failure due to reduced growth hormone secretion or insulin-like growth factor deficiency.
  • Musculoskeletal:
    • Arthritis, particularly affecting the second and third metacarpophalangeal joints.
    • Destructive arthropathy of hip and knee joints (10% of patients).
    • Chondrocalcinosis with pyrophosphate deposition.
    • Osteoporosis (detected by Dexa scan).
  • Cardiovascular: Cardiomyopathy and heart failure.
  • Dermatological: Slate-grey skin pigmentation caused by excess melanin deposition.
  • General: Fatigue.

Diagnosis and Monitoring

Iron Status Markers

  • Transferrin Saturation: Essential for early detection. A value of >45%>45\% indicates iron accumulation. It may be depressed during infection or inflammation.
  • Serum Ferritin: Rising values suggest overload. Thresholds are >200 μg/L>200\,\mu g/L for women and >300 μg/L>300\,\mu g/L for men. Values above 1000 μg/L1000\,\mu g/L in C282Y homozygotes make liver biopsy essential to assess damage.

Liver Assessment

  • Liver Biopsy:
    • Used to assess liver structure and iron burden (histologically via Perls stain and chemically).
    • Liver Iron Concentration (LIC): Values >80 μmol/g>80\,\mu mol/g dry weight (4.5 mg/g4.5\,mg/g dry weight) indicate overload.
    • Hepatic Iron Index: (μmol iron/g dry weight)/age in years(\mu mol\,iron/g\,dry\,weight) / \text{age in years}.
  • MRI (T2* Technique): A non-invasive method to measure liver and heart iron. It distinguishes between cardiac and liver iron deposition.
  • SQUID (Superconducting Quantum Interface Device): Sensitive biosusceptometry based on the paramagnetic properties of hemosiderin and ferritin. It does not distinguish parenchymal from reticuloendothelial iron.

Family and Population Screening

  • Family Testing: First-degree relatives should be tested via transferrin saturation, serum ferritin, and HFE genotyping.
  • Population Screening: Currently considered unwarranted for the general population due to low clinical penetrance in C282Y homozygotes.

Specific Forms of Type 4 (Ferroportin Disease)

  • Type 4a (Classic Ferroportin Disease):
    • Phenotype similar to anemia of chronic disease.
    • Iron accumulation predominantly in macrophages (Kupffer cells).
    • Normal or low transferrin saturation.
    • Caused by loss-of-function mutations preventing ferroportin from reaching the cell surface.
  • Type 4b:
    • Mutations occur in the hepcidin-binding site of ferroportin.
    • Ferroportin is resistant to hepcidin, causing increased iron export to plasma.
    • Phenotype similar to HFE haemochromatosis (parenchymal iron deposition).

Other Rare or Related Conditions

  • Neonatal Haemochromatosis: Recognized at birth or in utero; characterized by irreversible liver failure. Likely immunological pathogenesis (maternal alloantibodies).
  • African Iron Overload (Bantu Siderosis): Combination of dietary iron (traditional beer) and an unknown susceptibility gene. Associated with hepatic fibrosis, diabetes, scurvy, and osteoporosis.
  • Atransferrinaemia: Rare recessive disorder causing severe hypochromic anemia and non-transferrin-bound iron (NTBI) deposition.
  • Acaeruloplasminaemia: Deficiency in ferroxidase activity. Presents with retinal degeneration, basal ganglia degeneration, and diabetes. Serum iron is low, but iron accumulates in the brain and organs.
  • Hallervorden Spatz Syndrome (PKAN): Autosomal recessive neurodegeneration with brain iron accumulation. Caused by a pantothenate kinase gene defect.
  • Neuroferritinopathy: Dominantly inherited late-onset basal ganglia disease. Ferritin light-chain (FTL) gene mutation.
  • Friedreich Ataxia (FA): Mitochondrial iron overload and loss of iron-sulphur cluster-containing enzymes. Marked by sensory neuron loss and cardiomyopathy.

Iron Overload in Ineffective Erythropoiesis (IE)

  • Mechanism: Failure of RBC production leads to suppression of hepcidin via signals like Erythroferrone (ERFE), GDF15, and TWSG1 released by dying erythroblasts.
  • NTBI: When erythropoiesis cannot use iron, transferrin becomes saturated, leading to Non-Transferrin-Bound Iron (NTBI), which enters tissues in an unregulated manner.
  • Conditions: Thalassemia, Myelodysplastic Syndrome (MDS), and Congenital Dyserythropoietic Anaemias (CDAs).

Acute Iron Poisoning

  • Clinical Signs: Severe necrotizing gastritis/enteritis, metabolic acidosis, cardiovascular collapse, and liver damage.
  • Treatment: Oral and parenteral Deferoxamine (DFX). Gastric lavage with 1%1\% sodium bicarbonate may be used prior to instilling 5 g5\,g of DFX into the stomach.